HAE Haemonetics Corp

Price (delayed)

$65.26

Market cap

$3.35B

P/E Ratio

76.78

Dividend/share

N/A

EPS

$0.85

Enterprise value

$3.86B

Haemonetics is a global healthcare company dedicated to providing a suite of innovative medical products and solutions for customers, to help them improve patient care and reduce the cost of ...

Highlights
The price to earnings (P/E) is 51% lower than the 5-year quarterly average of 149.4 and 20% lower than the last 4 quarters average of 92.2
The company's gross profit rose by 27% YoY and by 12% QoQ
The company's EPS has surged by 98% QoQ but it fell by 46% YoY
HAE's net income has surged by 92% since the previous quarter but it is down by 45% year-on-year
The company's quick ratio fell by 25% YoY and by 14% QoQ
The debt is up by 9% year-on-year

Key stats

What are the main financial stats of HAE
Market
Shares outstanding
51.28M
Market cap
$3.35B
Enterprise value
$3.86B
Valuations
Price to earnings (P/E)
76.78
Price to book (P/B)
4.45
Price to sales (P/S)
3.35
EV/EBIT
47.81
EV/EBITDA
21.63
EV/Sales
3.89
Earnings
Revenue
$993.2M
EBIT
$80.75M
EBITDA
$178.5M
Free cash flow
$77.78M
Per share
EPS
$0.85
Free cash flow per share
$1.52
Book value per share
$14.66
Revenue per share
$19.46
TBVPS
$21.2
Balance sheet
Total assets
$1.86B
Total liabilities
$1.11B
Debt
$773.59M
Equity
$749.42M
Working capital
$313.77M
Liquidity
Debt to equity
1.03
Current ratio
1.71
Quick ratio
0.95
Net debt/EBITDA
2.88
Margins
EBITDA margin
18%
Gross margin
50.9%
Net margin
4.4%
Operating margin
8.1%
Efficiency
Return on assets
2.4%
Return on equity
6.1%
Return on invested capital
6.4%
Return on capital employed
5.7%
Return on sales
8.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HAE stock price

How has the Haemonetics stock price performed over time
Intraday
3.9%
1 week
7.39%
1 month
7.39%
1 year
0.38%
YTD
23.04%
QTD
3.23%

Financial performance

How have Haemonetics's revenue and profit performed over time
Revenue
$993.2M
Gross profit
$505.5M
Operating income
$80.75M
Net income
$43.38M
Gross margin
50.9%
Net margin
4.4%
The operating income has soared by 100% since the previous quarter but it is down by 10% year-on-year
The operating margin has soared by 93% from the previous quarter but it has contracted by 21% YoY
HAE's net income has surged by 92% since the previous quarter but it is down by 45% year-on-year
The net margin has soared by 83% since the previous quarter but it has dropped by 52% year-on-year

Growth

What is Haemonetics's growth rate over time

Valuation

What is Haemonetics stock price valuation
P/E
76.78
P/B
4.45
P/S
3.35
EV/EBIT
47.81
EV/EBITDA
21.63
EV/Sales
3.89
The company's EPS has surged by 98% QoQ but it fell by 46% YoY
The price to earnings (P/E) is 51% lower than the 5-year quarterly average of 149.4 and 20% lower than the last 4 quarters average of 92.2
The price to book (P/B) is 35% lower than the 5-year quarterly average of 6.6 and 7% lower than the last 4 quarters average of 4.6
The equity is up by 2.6% since the previous quarter and by 2.4% year-on-year
The stock's P/S is 31% less than its 5-year quarterly average of 4.7 and 8% less than its last 4 quarters average of 3.5
The revenue rose by 14% YoY and by 4.2% QoQ

Efficiency

How efficient is Haemonetics business performance
The company's return on invested capital has surged by 100% QoQ but it fell by 29% YoY
The company's return on assets has surged by 100% QoQ but it has shrunk by 55% YoY
The company's return on sales has surged by 93% QoQ but it fell by 21% YoY
HAE's return on equity has surged by 91% since the previous quarter but it is down by 48% year-on-year

Dividends

What is HAE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HAE.

Financial health

How did Haemonetics financials performed over time
The total assets is 67% more than the total liabilities
The current ratio has contracted by 38% YoY and by 17% from the previous quarter
The company's quick ratio fell by 25% YoY and by 14% QoQ
The debt is 3.2% greater than the equity
The debt is up by 9% year-on-year
The debt to equity has grown by 6% YoY but it has contracted by 2.8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.